A very detailed Option No 1 indeed:

"Option 1, Resverlogix will now finalize it’s ongoing negotiations with Major Pharmaceutical companies to determine a suitable partner for co-developing apabetalone. Codevelopment discussions include the following: ▪ Resverlogix will receive a significant upfront payment H2, 2020. ▪ The Phase 3b clinical trial will be funded by the partnering company - $120 to $150 MM USD. ▪ Our new partner can supply their SGLT2 diabetes drug as the co-medication. Thus providing the pharma partner with valuable marketing material and the ability to launch a fixed dose combination product with patent coverage until 2040. ▪ The deal will also include substantial milestone and royalty payments with an M&A right of first refusal option."

All we can do is wait this out. I guess Don is busy picking and choosing the best SGLT2 partner deal. This is the time to use up any dry powder.

Koo